Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Creative Educational Concepts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Creative Educational Concepts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Optimizing Cancer-related Anemia Outcomes in the Community Setting: Interprofessional Approaches and Evidence-supported Strategies for Improving Care with Intravenous Iron

49:32
 
Share
 

Manage episode 340683673 series 2870185
Content provided by Creative Educational Concepts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Creative Educational Concepts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Learning Objectives

  • Review the formative facets of iron absorption and metabolism, including the practical distinctions between functional and absolute iron deficiency, with expert analysis of how these principles dictate treatment approaches.
  • Summarize the multifactorial etiologies and complex pathophysiology of cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA), emphasizing the implications of CRA/CIA on oncologic outcomes and patient-centric metrics.
  • Appraise completed, ongoing, and planned clinical trials of IV iron products in CRA/CIA, highlighting the established ability of these agents to enhance hematopoietic response rates, decrease transfusion burden, and improve patient outcomes.
  • Discuss how next-generation IV iron products have dramatically improved upon the safety profiles of earlier generation agents, particularly with respect to severe hypersensitivity reactions.
  • Review current expert consensus guidelines for CRA/CIA management from ASCO/ASH, NCCN, and ESMO.
  • Use real-world patient cases to evaluate evidence-supported strategies that members of the multidisciplinary and interprofessional cancer care team can use to safely and effectively implement IV iron into clinical practice.
  • Compare and contrast the unique clinical utility of currently-approved IV iron agents, emphasizing the impact of differential safety profiles on treatment decisions.
  • Investigate the clinical implications of IV iron-associated hypophosphatemia in all patients, but especially in those with cancer and/or those actively receiving chemotherapy.

Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from Pharmacosmos Therapeutics, Inc.

  continue reading

35 episodes

Artwork
iconShare
 
Manage episode 340683673 series 2870185
Content provided by Creative Educational Concepts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Creative Educational Concepts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Learning Objectives

  • Review the formative facets of iron absorption and metabolism, including the practical distinctions between functional and absolute iron deficiency, with expert analysis of how these principles dictate treatment approaches.
  • Summarize the multifactorial etiologies and complex pathophysiology of cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA), emphasizing the implications of CRA/CIA on oncologic outcomes and patient-centric metrics.
  • Appraise completed, ongoing, and planned clinical trials of IV iron products in CRA/CIA, highlighting the established ability of these agents to enhance hematopoietic response rates, decrease transfusion burden, and improve patient outcomes.
  • Discuss how next-generation IV iron products have dramatically improved upon the safety profiles of earlier generation agents, particularly with respect to severe hypersensitivity reactions.
  • Review current expert consensus guidelines for CRA/CIA management from ASCO/ASH, NCCN, and ESMO.
  • Use real-world patient cases to evaluate evidence-supported strategies that members of the multidisciplinary and interprofessional cancer care team can use to safely and effectively implement IV iron into clinical practice.
  • Compare and contrast the unique clinical utility of currently-approved IV iron agents, emphasizing the impact of differential safety profiles on treatment decisions.
  • Investigate the clinical implications of IV iron-associated hypophosphatemia in all patients, but especially in those with cancer and/or those actively receiving chemotherapy.

Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from Pharmacosmos Therapeutics, Inc.

  continue reading

35 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play